Clinical Trial Update: Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 trial investigating biomarkers for conversion risk and treatment response in early-stage schizophrenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Schizophrenia Spectrum and Other Psychotic Disorders | Phase 4 | Status: COMPLETED | Results posted: 2024-05-06